» Articles » PMID: 22267590

MicroRNA-221/222 Upregulation Indicates the Activation of Stellate Cells and the Progression of Liver Fibrosis

Overview
Journal Gut
Specialty Gastroenterology
Date 2012 Jan 24
PMID 22267590
Citations 114
Authors
Affiliations
Soon will be listed here.
Abstract

Background: MicroRNAs (miRNAs) are important in hepatic pathophysiology and the development of liver cancer.

Objective: To explore miRNAs that are regulated with the progression of liver fibrosis caused by chronic liver disease.

Design: The regulated miRNAs in human livers infected with hepatitis C virus were identified by microarray analysis. Their expression in human livers with non-alcoholic steatohepatitis, mouse livers from two fibrosis models and cultured stellate cells was validated by real-time RT-PCR. The regulation of miR-222 expression in stellate cells by nuclear factor kappa B (NF-κB) was assayed. Finally, the effects of an miR-222 precursor or inhibitor on the expression of cyclin-dependent kinase inhibitor 1B (CDKN1B) and the growth of LX-2 cells were determined.

Results: It was found that miR-199a-5p/199a-3p and miR-221/222 were upregulated in the human liver in a fibrosis progression-dependent manner. Among these miRNAs, miR-221/222 were upregulated in LX-2 cells and increased during the course of culture-dependent activation of mouse primary stellate cells, in a manner similar to the expression of α1(I) collagen and α-smooth muscle actin mRNAs. The expression of miR-221/222 increased in mouse models of liver fibrosis. In contrast, an NF-κB inhibitor significantly suppressed the miR-222 induction that was stimulated in culture by transforming growth factor α or tumour necrosis factor α. Although overexpression or downregulation of miR-222 failed to regulate the growth of LX-2 cells, miR-222 bound to the CDKN1B 3'UTR and regulated the expression of the corresponding protein.

Conclusion: miR-221/222 may be new markers for stellate cell activation and liver fibrosis progression.

Citing Articles

From fatty liver to fibrosis: the impact of miRNAs on NAFLD and NASH.

Mansour R, Mageed S, Abulsoud A, Sayed G, Lutfy R, Awad F Funct Integr Genomics. 2025; 25(1):30.

PMID: 39888504 DOI: 10.1007/s10142-025-01544-x.


The interactive role of microRNA and other non-coding RNA in hepatitis B (HBV) associated fibrogenesis.

Sartorius K, Wang Y, Sartorius B, Antwi S, Li X, Chuturgoon A Funct Integr Genomics. 2025; 25(1):24.

PMID: 39847120 DOI: 10.1007/s10142-024-01519-4.


miRNA-221: A Potential Biomarker of Progressive Liver Injury in Chronic Liver Disease (CLD) due to Hepatitis B Virus (HBV) and Nonalcoholic Fatty Liver Disease (NAFLD).

Sutradhar P, Sultana N, Nessa A Int J Hepatol. 2024; 2024:4221368.

PMID: 39185365 PMC: 11343628. DOI: 10.1155/2024/4221368.


miR-9-5p and miR-221-3p Promote Human Mesenchymal Stem Cells to Alleviate Carbon Tetrachloride-Induced Liver Injury by Enhancing Human Mesenchymal Stem Cell Engraftment and Inhibiting Hepatic Stellate Cell Activation.

He L, Xu J, Huang P, Bai Y, Chen H, Xu X Int J Mol Sci. 2024; 25(13).

PMID: 39000343 PMC: 11241704. DOI: 10.3390/ijms25137235.


The role of microRNAs in hepatocellular carcinoma: Therapeutic targeting of tumor suppressor and oncogenic genes.

Farsi N, Naghipour B, Shahabi P, Safaralizadeh R, Hajiasgharzadeh K, Dastmalchi N Clin Exp Hepatol. 2024; 9(4):307-319.

PMID: 38774201 PMC: 11103798. DOI: 10.5114/ceh.2023.131669.